Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13362007 | 0.83 | NPC1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL27969014 | 0.80 | HTR1D (0.31) | — | |
| SCHEMBL3339715 | 0.71 | — | — | |
| SCHEMBL668146 | 0.69 | — | — | |
| SCHEMBL1106084 | 0.69 | CA2 (0.33) | — | |
| SCHEMBL12792919 | 0.69 | TSHR (0.31) | — | |
| SCHEMBL319464 | 0.69 | — | — | |
| SCHEMBL24373233 | 0.67 | MEN1 (0.31) | — | |
| SCHEMBL21719186 | 0.67 | AHR (0.32) | — | |
| SCHEMBL21737116 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023010123-A1 | PLACENTA-DERVIED NK CELLS AS A SENOLYTIC FOR THERAPEUTIC AND OTHER USES | CELULARITY INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20120157403-A1 | BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS | CHACKALAMANNIL SAMUEL (US) | 2012-06-21 | — | — | US | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| US-20100261750-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100249180-A1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | XANTHUS PHARMACEUTICALS, INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | GABRA1 1565/4885GABRB2 1052/4885HTR1A 403/4885 |
| US-20100249180-A1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | CFTR, ABCB1, ABCC8 | GABRA1 1072/4885GABRB2 487/4885HTR1A 4138/4885 |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | PMP22, PML, AQP4 | GABRA1 1270/4885GABRB2 740/4885HTR1A 4823/4885 |
| US-20120157403-A1 | BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS | EDNRB, TBXA2R, BDKRB1 | GABRA1 417/4885GABRB2 408/4885HTR1A 533/4885 |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | GABRA1 730/4885GABRB2 349/4885HTR1A 3291/4885 |
| US-20100261750-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, ABCB1, ABCC1 | GABRA1 923/4885GABRB2 265/4885HTR1A 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.